March 4, 2008 -- Simcere Pharma (NYSE: SCR) reported solid Q4 and 2007 results, and the company significantly increased its guidance for 2008. Simcere manufactures branded generic drugs, the patented cancer statin drug, Endu, and a treatment for stroke, Bicun. In 2007, Simcere generated revenues of 1.39 billion RMB ($190.5 million), an increase of 46% over 2006. Net income came in at 301 million RMB ($41.3 million) for the year, a 75% jump from 2006. Simcere is now predicting it will generate revenues in a range from 2 billion RMB to 2.1 billion RMB in 2008, with profits between 390 million RMB and 400 million RMB. More details...
